Exploring the Molecular Mechanism Based on KIT Mutation (EMMBKM)

NCT05895942 UNKNOWN

Imatinib remains suboptimal for recurrence/metastasis and unresectable GIST response rates. With the maturity of genomics and metabolomics, people gradually realize the role of gut microbiota in tumor therapy. The gut microbiota may affect tumor treatment by regulating the tumor microenvironment or the host immune system, and some bacteria can fight tumors by activating the immune system. Growing evidence shows that the effect of tumor therapy is related to the composition of the gut microbiota of patients, and that the composition of the gut microbiota of patients sensitive to drug treatment has certain characteristics, and these characteristics may be used as biomarkers to predict the prognosis of treatment. At present, it remains unclear whether the efficacy of imatinib is related to the gut microbiota in GIST patients. Therefore, precise mining of microbial information and the development of reasonable and feasible microbial interventions are expected to optimize the treatment strategy of GIST to a large extent and provide a basis for individualized treatment of advanced GIST.

Details

Lead sponsor	Xijing Hospital
Status	UNKNOWN
Enrolment	190
Start date	Fri Sep 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• GIST

Interventions

• Imatinib

Countries

China